1-乙基-4-氧代-1,4-二氢喹啉-3-羧酸 | 23789-88-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 1-乙基-4-氧代-1,4-二氢喹啉-3-羧酸
• 中文别名: 1-乙基-4-氧代-3-喹啉羧酸
• 英文名称: 1-ethyl-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid
• 英文别名: 1-ethyl-4-oxo-1,4-dihydroquinoline-3-carboxylic acid；1-ethyl-4-quinolone-3-carboxylic acid；1,4-dihydro-1-ethyl-4-oxoquinoline-3-carboxylic acid；1-ethyl-4-oxoquinoline-3-carboxylic acid
• CAS: 23789-88-0
• 化学式: C₁₂H₁₁NO₃
• mdl: MFCD00667561
• 分子量: 217.224
• InChiKey: ZSEJADLCFCHIGX-UHFFFAOYSA-N

物化性质

• 熔点：
  253-254 °C (decomp)(Solv: N,N-dimethylformamide (68-12-2))
• 沸点：
  357.8±42.0 °C(Predicted)
• 密度：
  1.317±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  57.6
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2933499090

反应信息

• 作为反应物：
  描述：

  1-乙基-4-氧代-1,4-二氢喹啉-3-羧酸 在 氨 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 生成 1-ethyl-4-oxoquinoline-3-carboxamide
  参考文献：
  名称：

  3-喹啉羧酰胺。一系列新型口服活性抗疱疹药。

  摘要：

  在结构上类似于喹诺酮类抗菌剂的一系列新型3-喹啉羧酰胺具有出色的抗疱疹性能。通过在1、2、3和7位修饰喹啉环，鉴定出与无环鸟苷相比具有高达5倍的HSV-2斑块减少能力的类似物。在单剂量小鼠感染模型中，体外最有效的衍生物之一是1-（4-氟苯基）-1,4-二氢-4-氧代-7-（4-吡啶基）-3-喹啉羰基乙酰胺（ 97），在1/16剂量下显示出与阿昔洛韦相当的口服抗疱疹药功效；然而，在多剂量方案中，97的效力降低了2倍。在口服97次的小鼠中，血浆药物水平持续升高很明显，这可能是观察到的高疗效的原因。这些药物作用的分子机理尚不清楚；然而，基于对阿昔洛韦抗性突变体的体外研究，其机理可能与阿昔洛韦不同。体外减轻斑块的能力通常不能预测小鼠的口服功效。X射线晶体结构97证实了结构的指定，并提供了有关构象对减少斑块效力的影响的有用见解。

  DOI：

  10.1021/jm00063a008
• 作为产物：
  描述：

  4-氧代-1,4-二氢喹啉-3-羧酸 在 水 、 caesium carbonate 、 sodium hydroxide 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 17.17h， 生成 1-乙基-4-氧代-1,4-二氢喹啉-3-羧酸
  参考文献：
  名称：

  Structural development of a type-1 ryanodine receptor (RyR1) Ca2+-release channel inhibitor guided by endoplasmic reticulum Ca2+ assay

  摘要：

  Type-1 ryanodine receptor (RyRI) is a calcium-release channel localized on sarcoplasmic reticulum (SR) of the skeletal muscle, and mediates muscle contraction by releasing Ca2+ from the SR. Genetic mutations of RyRI are associated with skeletal muscle diseases such as malignant hyperthermia and central core diseases, in which over-activation of RyRI causes leakage of Ca2+ from the SR. We recently developed an efficient high-throughput screening system based on the measurement of Ca2+ in endoplasmic reticulum, and used it to identify oxolinic acid (1) as a novel RyRI channel inhibitor. Here, we designed and synthesized a series of quinolone derivatives based on 1 as a lead compound. Derivatives bearing a long alkyl chain at the nitrogen atom of the quinolone ring and having a suitable substituent at the 7-position of quinolone exhibited potent RyR1 channel-inhibitory activity. Among the synthesized compounds, 14h showed more potent activity than dantrolene, a known RyR1 inhibitor, and exhibited high RyR1 selectivity over RyR2 and RyR3. These compounds may be promising leads for clinically applicable RyRI channel inhibitors. (C) 2019 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2019.06.076

文献信息

• [EN] AGENTS FOR USE IN THE TREATMENT OF CARDIOVASCULAR AND INFLAMMATORY DISEASES STRUCTURALLY BASED ON 4(1 H)-QUINOLONE<br/>[FR] AGENTS DESTINÉS À ÊTRE UTILISÉS DANS LE TRAITEMENT DE MALADIES CARDIOVASCULAIRES ET INFLAMMATOIRES AYANT UNE STRUCTURE BASÉE SUR LA 4(1H)-QUINOLONE
  申请人：UCL BUSINESS PLC

  公开号：WO2015189560A1

  公开（公告）日：2015-12-17

  The present invention provides a compound of formula I, a tautomer thereof, or a pharmaceutically acceptable salt or N-oxide thereof for use in the treatment or prevention of a cardiovascular disease or of an inflammatory disease or condition:

  本发明提供了一种式I的化合物，其互变异构体，或其药用可接受的盐或N-氧化物，用于治疗或预防心血管疾病或炎症性疾病或症状。
• A new organosilylpolyphosphoric reagent, its preparation and application to the process of synthesis of 3-carboxyquinolones or azaquinolones and their salts
  申请人：CENTRO MARGA PARA LA INVESTIGACION S.A.

  公开号：EP0376870A1

  公开（公告）日：1990-07-04

  A process for the preparation of new organosilylpoly­phosphates from the reaction of phosphorus pentoxide with a siloxane or alkyloxysilane to obtain, in solution, reagents the composition of which is [P₂O₅]N[SILANE], where 1 < N < 10 where N is a function of temperatu­re, reaction time and solvent, being applied to the modulation of cyclization reaction of N-susbtituted aminomethylenemalonates leading to quinolones or azaqui­nolones. The N-substituted aminomethylenemalonates are prepared by the reaction of anilines with dialkyl trimethylsilyloxy­methylene-malonates.

  一种制备新的有机硅聚磷酸酯的方法，通过磷五氧化物与硅氧烷或烷氧基硅烷的反应得到溶液中的试剂，其组成为[P₂O₅]N[SILANE]，其中1 < N < 10，N是温度、反应时间和溶剂的函数，用于调节N-取代氨基亚甲基丙二酸酯的环化反应，形成喹啉酮或氮代喹啉酮。N-取代氨基亚甲基丙二酸酯是通过苯胺与二烷基三甲基硅氧基亚甲基丙二酸酯的反应制备的。
• Pharmacologically active amides and esters containing an
  申请人：John Wyeth & Brother Limited

  公开号：US05096901A1

  公开（公告）日：1992-03-17

  Compounds of formula ##STR1## wherein R.sup.1 is hydrogen or one or more specified substituents, X is --O-- or --NR.sup.2 -- where R.sup.2 is lower alkyl, lower alkenyl, lower alkynyl, aryl or specified substituted lower alkyl or R.sup.2 represents a group --Z-- which is connected to the 8-position of the aromatic ring so as to form a heterocyclic ring of 5 to 7 ring members, Y is O or NR.sup.3 where R.sup.3 is hydrogen or lower alkyl, and B is a saturated azabicyclic ring (eg tropanyl or quinuclidinyl) or a N-oxide thereof and their acid addition salts are 5-HT.sub.3 antagonists which may be used in, for example, the treatment of neuro-psychiatric disorders.

  式为##STR1##的化合物，其中R.sup.1是氢或一个或多个指定的取代基，X是--O--或--NR.sup.2 --，其中R.sup.2是较低的烷基、较低的烯基、较低的炔基、芳基或指定的取代的较低烷基，或R.sup.2代表一个连接到芳香环的8位的--Z--基团，以形成5至7个环成员的杂环环，Y是O或NR.sup.3，其中R.sup.3是氢或较低的烷基，B是饱和的氮杂双环环（例如环丙基或喹诺啉基）或其酸盐，它们是5-HT.sub.3拮抗剂，可用于治疗神经精神障碍。
• Studies on the Interaction of Pyridone Carboxylic Acids with Metals.
  作者：Yoshito OKABAYASHI、Fumiaki HAYASHI、Yoshihiro TERUI、Takayasu KITAGAWA

  DOI：10.1248/cpb.40.692

  日期：——

  The stability constants of metal complexes for several pyridone carboxylic acid drugs (ofloxacin, norfloxacin and lomefloxacin) were determined by potentiometry and spectrophotometry. The values of aluminum complexes, magnesium complexes and calcium complexes were CaZn). The stability constants of metal complexes for several pyridone carboxylic acids synthesized were also determined and compared with those for pyridone carboxylic adic drugs. The stability constants of these compounds gradually increased with an increasing pKa value of the carboxyl group of pyridone carboxylic acid. In the case of aluminum complexes, the complexes Al(OH)L and Al(OH)2L were formed under weak acidic conditions and the dissociation constants for the hydrolysis of the aluminum complexes were determined. The participation of the carboxyl group and the carbonyl group in the chelating reaction was confirmed by the measurement of carbon-13 nuclear magnetic resonance of the aluminum complex and the magnesium complex. These results suggest that when pyridone carboxylic acids are administered with metallic antacid containing aluminum hydroxide and magnesium oxide, aluminum complexes AIL, Al(OH)L or Al(OH)2L are formed and the adsorption of the drugs in the intestines is reduced.

  通过电位法和分光光度法测定了几种吡啶酮羧酸类药物（氧氟沙星、诺氟沙星和洛美沙星）的金属络合物稳定常数。铝络合物、镁络合物和钙络合物的值为 CaZn）。此外，还测定了合成的几种吡啶酮羧酸的金属络合物的稳定常数，并与吡啶酮羧酸类药物的稳定常数进行了比较。这些化合物的稳定常数随着吡啶酮羧酸羧基 pKa 值的增加而逐渐增大。就铝络合物而言，在弱酸性条件下形成了络合物 Al(OH)L 和 Al(OH)2L，并测定了铝络合物水解时的解离常数。通过测量铝络合物和镁络合物的碳 13 核磁共振，证实了羧基和羰基参与了螯合反应。这些结果表明，吡啶酮羧酸与含有氢氧化铝和氧化镁的金属抗酸剂一起服用时，会形成铝络合物 AIL、Al(OH)L 或 Al(OH)2L，从而减少药物在肠道中的吸附。
• MCR Synthesis of Praziquantel Derivatives
  作者：Haixia Liu、Samia William、Eberhardt Herdtweck、Sanaa Botros、Alexander Dömling

  DOI：10.1111/j.1747-0285.2011.01288.x

  日期：2012.4

  Schistosomiasis, a high volume neglected tropical disease affecting more than 200 million people worldwide, can only be effectively treated by the tetrahydroisoquinoline drug praziquantel (PZQ). Herein, we describe an efficient approach to access PZQ derivatives by the Ugi 4‐component reaction followed by the Pictet–Spengler reaction in a two‐step, one‐pot procedure. 30 novel PZQ derivatives are described

  血吸虫病是一种影响全球 2 亿多人的大量被忽视的热带疾病，只能通过四氢异喹啉药物吡喹酮 (PZQ) 进行有效治疗。在此，我们描述了一种通过 Ugi 4 组分反应和 Pictet-Spengler 反应在两步单锅程序中获得 PZQ 衍生物的有效方法。基于 Ugi 4 组分反应描述了 30 种新型 PZQ 衍生物，并讨论了一种新型衍生物的 X 射线结构，与 PZQ 相比，揭示了不同的构象。基于体外曼氏血吸虫蠕虫活力测定，已经确定了几种在活性上与药物 PZQ 相当的类似物。